433711-95-6

Basic information

• Product Name: (2-BROMO-PYRIDIN-4-YL)CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: 4-(BOC-AMINO)-2-BROMOPYRIDINE;2-BROMO-4-BOC PYRIDINE;(2-BROMO-PYRIDIN-4-YL)CARBAMIC ACID TERT-BUTYL ESTER;2-Bromo-4-(tert-butoxycarbonylamino)pyridine;N-Boc-4-amino-2-bromopyridine;Tert-butyl 2-bromopyridin-4-ylcarbamate;Zinc02511835;(2-BROMO-PYRIDIN-4-Y
• CAS NO: 433711-95-6
• Molecular Formula: C₁₀H₁₃BrN₂O₂
• Molecular Weight: 273.13
• Product Categories: Heterocycle-Pyridine series
• Mol File: 433711-95-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 299.3 °C at 760 mmHg
• Flash Point: 134.8 °C
• Appearance: white powder
• Density: 1.453 g/cm³
• Vapor Pressure: 0.0012mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: 2-8°C
• PKA: 11.97±0.70(Predicted)
• CAS DataBase Reference: (2-BROMO-PYRIDIN-4-YL)CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (2-BROMO-PYRIDIN-4-YL)CARBAMIC ACID TERT-BUTYL ESTER(433711-95-6)
• EPA Substance Registry System: (2-BROMO-PYRIDIN-4-YL)CARBAMIC ACID TERT-BUTYL ESTER(433711-95-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• Safety Statements: 24/25
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 433711-95-6(Hazardous Substances Data)

Usage

General Description

(2-Bromo-pyridin-4-yl)carbamic acid tert-butyl ester is a chemical compound with the molecular formula C10H12BrN2O2. It is a carbamate ester derivative of 2-bromo-4-pyridinecarboxylic acid, and is used in the synthesis of pharmaceuticals and agrochemicals. (2-BROMO-PYRIDIN-4-YL)CARBAMIC ACID TERT-BUTYL ESTER is commonly used as a building block in organic synthesis, and its tert-butyl ester group provides stability and protection to the reactive pyridine carboxylic acid moiety. It is important to handle this chemical with care and in accordance with proper safety protocols, as it may pose hazards if not handled properly.

InChI:InChI=1/C10H13BrN2O2/c1-10(2,3)15-9(14)13-7-4-5-12-8(11)6-7/h4-6H,1-3H3,(H,12,13,14)

Upstream product

• 6945-67-1 2-bromo-4-nitropyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 7598-35-8 2-bromo-4-aminopyridine 

Downstream Products

• 1259524-93-0 tert-butyl (2-(phenylethynyl)pyridin-4-yl)carbamate 
• 1350648-27-9 2-(5-chloro-2,4-difluorophenyl)pyridin-4-amine 
• 1350648-36-0 2-(2-fluoro-5-methylphenyl)pyridin-4-amine 
• 1350646-62-6 N-(2-(2-fluoro-5-methylphenyl)pyridin-4-yl)-2-(1-(methylsulfonyl)piperidin-4-yl)-2H-pyrazolo[4,3-b]pyridin-7-amine 
• 1350646-61-5 N-(2-(2-fluoro-5-methylphenyl)pyridin-4-yl)-1-(1-(methylsulfonyl)piperidin-4-yl)-1H-pyrazolo[4,3-b]pyridin-7-amine 
• 1350646-60-4 N-(2-(2-fluoro-5-methylphenyl)pyridin-4-yl)-2-(piperidin-4-yl)-2H-pyrazolo[4,3-b]pyridin-7-amine 
• 1350646-59-1 N-(2-(2-fluoro-5-methylphenyl)pyridin-4-yl)-1-(piperidin-4-yl)-1H-pyrazolo[4,3-b]pyridin-7-amine 

Relevant articles and documents

Characterization and Optimization of Benzimidazopyrimidine and Pyridoimidazopyridine Derivatives as Tau-SPECT Probes

The accumulation of hyperphosphorylated tau protein in the brain is regarded as one of the hallmarks of Alzheimer's disease (AD). In vivo imaging of tau aggregates is helpful for diagnosis and monitoring of the progression of AD. In this study, we designed and synthesized novel radioiodinated benzimidazopyrimidine (BIPM) and pyridoimidazopyridine (PIP) derivatives with a monomethylamino, monoethylamino, monopropylamino, or diethylamino group as tau imaging probes for single-photon-emission computed tomography (SPECT). On in vitro autoradiography with AD brain sections, [125I]PIP-NHMe showed the highest selective binding affinity for tau aggregates among the radioiodinated BIPM and PIP derivatives. In a biodistribution study using normal mice, [125I]PIP-NHMe and [125I]PIP-NHEt displayed high initial uptake (6.62 and 6.86% ID/g, respectively, at 2 min postinjection) into and rapid clearance from the brain, with brain2 min/brain30 min ratios of 38.9 and 28.6, respectively. These results suggest that [123I]PIP-NHMe may be a novel SPECT probe that is useful for detecting tau aggregates in the AD brain.

FNEW ACTIVATORS OF SIRT1 ENZYME FOR THE TREATMENT OF CARDIOVASCULAR AND CARDIOMETABOLIC PATHOLOGIES

This invention describes a class of compounds able to activate the human SIRT1 enzyme and regulate many metabolic functions. This invention relates to compounds that can be employed in medical applications, specifically for the treatment or prevention of cardiometabolic diseases, such as diabetes, and of cardiovascular disorders, such as coronaropathy, heart failure and atherosclerosis.

Pyridylphosphinate metal complexes: Synthesis, structural characterisation and biological activity

For the first time, a series of 25 pseudo-octahedral pyridylphosphinate metal complexes (Ru, Os, Rh, Ir) has been synthesised and assessed in biological systems. Each metal complex incorporates a pyridylphosphinate ligand, a monodentate halide and a capping η6-bound aromatic ligand. Solid- and solution-state analyses of two complexes reveal a structural preference for one of a possible two diastereomers. The metal chlorides hydrolyse rapidly in D2O to form a 1:1 equilibrium ratio between the aqua and chloride adducts. The pKa of the aqua adduct depends upon the pyridyl substituent and the metal but has little dependence upon the phosphinate R′ group. Toxicity was measured in vitro against non-small cell lung carcinoma H460 cells, with the most potent complexes reporting IC50 values around 50 μM. Binding studies with selected amino acids and nucleobases provide a rationale for the variation in toxicity observed within the series. Finally, an investigation into the ability of the chelating amino acid l-His to displace the phosphinate O-metal bond shows the potential for phosphinate complexes to act as prodrugs that can be activated in the intracellular environment.